WHO ICTRP trial
Observational clinical study of camrelizumab combined with apatinib and TACE in…
ChiCTR2100049661 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100049661 |
|---|---|
| Public title | Observational clinical study of camrelizumab combined with apatinib and TACE in adjuvant treatment of patients with high risk of recurrence after radical hepatocellular carcinoma |
| Scientific title | Observational clinical study of camrelizumab combined with apatinib and TACE in adjuvant treatment of patients with high risk of recurrence after radical hepatocellular carcinoma |
| Primary sponsor | First Affiliated Hospital of Zhengzhou University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | hepatocellular carcinoma |
| Interventions | Experimental group:Camrelizumab+apatinib+TACE;Control group:TACE |
| Registration date | Aug 7, 2021 |
| Target size | Experimental group:70;Control group:70 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: